Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Matinas BioPharma Holdings Inc

MTNB ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$3.01

▲ +6.74%

Market Cap $2.95M · Vol 18.83K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.95M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

62.16

Momentum

Beta

2.21

vs Market

52W High

$29.25

89.71% below

52W Low

$2.33

29.46% above

Volume

18.83K

Avg 5.31K

P/B

0.78

Price-to-book

ROE

N/A

Return on equity

Free Float

76.25%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Matinas BioPharma Holdings Inc (MTNB) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MTNB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.51%

+10.26%

-68.05%

-63.52%

YTD

-65.76%

-89.45%

-97.84%

-99.62%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-10,345,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-104.24% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.78
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	979.52K

Technical Indicators

50-Day SMA	$3.17
200-Day SMA	$7.71
RSI (14)	62.16
Beta	2.21
52-Week High	$29.25
52-Week Low	$2.33

Volume Today	18.83K
Avg Daily Volume (30D)	5.31K
Relative Volume	3.54x
Volatility (10D)	126.00
Volatility (30D)	106.30
Free Float	76.25%

Analyst Consensus

N/A

Current Price $3.01

Mean Target N/A

52W Low$2.33 52W High$29.25

Current

Target

$2.33 $29.25

Current Analyst target

· 0 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG005WX2XH7

ISINUS5768103039

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.92% ARGX.BR argenx SE +2.76% ARGX argenx SE +1.93% 2269.HK WuXi Biologics (Cayman) Inc. +4.51% GMAB Genmab A/S -1.77%

Company Profile

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.